Jabil and Kymanox Announce Collaboration to Deliver End-to-End Development, Regulatory, and Manufacturing Solutions for Pharma, Biotech

ST. PETERSBURG, Fla. and MORRISVILLE, N.C. – October 28, 2025 – Jabil Inc. (NYSE: JBL), the world’s largest healthcare manufacturing solutions provider, and Kymanox Corporation, a professional services company dedicated exclusively to serving life sciences, today announced they have entered into a non-exclusive collaboration to support companies developing and commercializing drug-device combination products and other complex life science innovations.

Companies with cutting-edge pharmaceutical or device technologies may lack the in-house expertise to navigate the next steps of drug development. These include lengthy and expensive regulatory pathways, comprehensive testing, complex manufacturing, and supply chain management. Jabil and Kymanox can bridge that gap through their combined capabilities across the full product lifecycle.

“With the acquisition of Pharmaceutics International, Inc. (Pii) in February, Jabil established itself in the CDMO realm, adding new drug product development and sterile fill-finish capabilities to our portfolio. Our collaboration with Kymanox takes this a step further — enabling us to offer pharmaceutical customers early-stage support with regulatory strategy and development to complement Jabil’s existing regulatory, development, commercialization, manufacturing, and packaging services,” said Mike Mahaz, SVP, Global Business Units, Healthcare, at Jabil. “Jabil and Kymanox can help pharma and biotech innovators manage complexity, accelerate timelines, and deliver life-changing therapies to patients worldwide.”

“This collaboration allows us to leverage Kymanox’s deep technical and regulatory expertise with Jabil’s drug and device development, industrialization, and world-class manufacturing capabilities,” said Nicholas Ciccarelli, Chief Technology Officer at Kymanox. “Together, we can help clients move more efficiently from pre-clinical to commercial — ensuring that promising therapies reach patients faster.”

About Jabil:

At Jabil (NYSE: JBL), we are proud to be a trusted partner for the world’s top brands, offering comprehensive engineering, supply chain, and manufacturing solutions. With over 50 years of experience across industries and a vast network of over 100 sites worldwide, Jabil combines global reach with local expertise to deliver both scalable and customized solutions. Our commitment extends beyond business success as we strive to build sustainable processes that minimize environmental impact and foster vibrant and diverse communities around the globe. Discover more at www.jabil.com.

About Kymanox:

Kymanox® is a global life science professional services firm dedicated to accelerating the development and delivery of modern medicines. We provide proven, end-to-end solutions that help bring life science products to market—and keep them there. Our global team supports clients in Design, Development & Testing; Quality & Compliance; and Facilities Readiness, specifically in the areas of Biologics & Advanced Therapies and Combination Products. From pre-clinical to post-market, Kymanox de-risks challenges, ensures readiness, and advances innovation—because patients deserve better. For more information, visit www.kymanox.com.

# # #

Media Contact
Timur Aydin
Senior Director, Enterprise Marketing and Communications
Jabil
[email protected]

Michelle Frakes, PhD
Senior Director, Business Solutions & Marketing
Kymanox
[email protected]